A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas
Clinical trial NCT07750353 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07750353
- Sponsor
- National Cancer Center, Japan
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2027-02-01
- Primary completion
- 2029-12-01
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.